PMID- 11745679
OWN - NLM
STAT- MEDLINE
DCOM- 20020204
LR  - 20131121
IS  - 0022-3417 (Print)
IS  - 0022-3417 (Linking)
VI  - 195
IP  - 4
DP  - 2001 Nov
TI  - Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in 
      gastrointestinal endocrine tumours.
PG  - 463-72
AB  - Neuroendocrine tumours are characterized by their capacity to produce hormones, 
      which are stored in vesicles and secretory granules. Demonstration of 
      granule/vesicle proteins in tumours is taken as evidence of neuroendocrine 
      differentiation. Vesicular monoamine transporters (VMAT1 and VMAT2) mediate the 
      transport of amines into vesicles of neurons and endocrine cells. The expression 
      of VMAT1 and VMAT2 and the usefulness of VMAT1 and VMAT2 in the histopathological 
      diagnosis of gastrointestinal endocrine tumours have not been fully explored. 
      This study therefore investigated the expression of VMAT1 and VMAT2 in 211 human 
      gastrointestinal tumours by immunocytochemistry and western blotting. VMAT1 
      and/or VMAT2 were demonstrated in the majority of amine-producing endocrine 
      tumours of gastric, ileal, and appendiceal origin. Serotonin-producing endocrine 
      tumours (ileal and appendiceal carcinoids) expressed predominantly VMAT1, while 
      histamine-producing endocrine tumours (gastric carcinoids) expressed VMAT2 almost 
      exclusively. In peptide-producing endocrine tumours such as rectal carcinoids and 
      endocrine pancreatic tumours, only a small number of immunopositive tumour cells 
      were observed. No labelling was found in non-endocrine tumours, including 
      gastric, colorectal and pancreatic adenocarcinomas and gastrointestinal stromal 
      tumours. In conclusion, VMAT1 and VMAT2 are differentially expressed by 
      gastrointestinal endocrine tumours, with a pattern specific for each tumour type, 
      reflecting their neuroendocrine differentiation and origin. VMAT1 and VMAT2 may 
      therefore become valuable markers in the classification of neuroendocrine tumours 
      and may also indicate patients suitable for radioisotope treatment operating via 
      these transporter systems.
CI  - Copyright 2001 John Wiley & Sons, Ltd.
FAU - Jakobsen, A M
AU  - Jakobsen AM
AD  - Lundberg Laboratory for Cancer Research, University of Goteborg, Sweden.
FAU - Andersson, P
AU  - Andersson P
FAU - Saglik, G
AU  - Saglik G
FAU - Andersson, E
AU  - Andersson E
FAU - Kolby, L
AU  - Kolby L
FAU - Erickson, J D
AU  - Erickson JD
FAU - Forssell-Aronsson, E
AU  - Forssell-Aronsson E
FAU - Wangberg, B
AU  - Wangberg B
FAU - Ahlman, H
AU  - Ahlman H
FAU - Nilsson, O
AU  - Nilsson O
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pathol
JT  - The Journal of pathology
JID - 0204634
RN  - 0 (Chromogranin A)
RN  - 0 (Chromogranins)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Neuropeptides)
RN  - 0 (SLC18A1 protein, human)
RN  - 0 (SLC18A2 protein, human)
RN  - 0 (Vesicular Biogenic Amine Transport Proteins)
RN  - 0 (Vesicular Monoamine Transport Proteins)
RN  - 333DO1RDJY (Serotonin)
RN  - EC 1.14.16.2 (Tyrosine 3-Monooxygenase)
SB  - IM
MH  - Blotting, Western
MH  - Case-Control Studies
MH  - Chromogranin A
MH  - Chromogranins/metabolism
MH  - Gastrointestinal Neoplasms/*metabolism
MH  - Humans
MH  - Membrane Glycoproteins/*metabolism
MH  - *Membrane Transport Proteins
MH  - Neuroendocrine Tumors/*metabolism
MH  - *Neuropeptides
MH  - Serotonin/metabolism
MH  - Tyrosine 3-Monooxygenase/metabolism
MH  - Vesicular Biogenic Amine Transport Proteins
MH  - Vesicular Monoamine Transport Proteins
EDAT- 2001/12/18 10:00
MHDA- 2002/02/05 10:01
CRDT- 2001/12/18 10:00
PHST- 2001/12/18 10:00 [pubmed]
PHST- 2002/02/05 10:01 [medline]
PHST- 2001/12/18 10:00 [entrez]
AID - 10.1002/path.973 [pii]
AID - 10.1002/path.973 [doi]
PST - ppublish
SO  - J Pathol. 2001 Nov;195(4):463-72. doi: 10.1002/path.973.